Novita Pharmaceuticals to Present its Fascin Inhibitor NP-G2-044 Phase 1A Results in Patients with Advanced and Metastatic Solid Tumors at 2021 ASCO Annual Meeting
May 20, 2021Novita Pharmaceuticals, Inc. (“Novita” or the “Company”), a privately held clinical-stage biopharmaceutical company, is dedicated to developing cancer drugs based on its proprietary fascin inhibitor technology....
